semaglutide for prediabetes Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Semaglutide 2.4 mg clinical outcomes

The NDA for Wegovy was submitted in December 2020, before the pivotal trial was even published

A rat study found that at equivalent doses, sublingual semaglutide achieved significantly higher area under the curve (AUC) than oral administration: 82.53 vs 15.08 ng*h/mL

B2 cells that participate in the immune system are pro-inflammatory factors that can promote NASH-associated liver fibrosis ( H 2 and T H 17 cells have a pro-fibrogenic impact ( H 17 can stimulate the formation of transforming growth factor- (TGF-), which promotes fibrosis by activating fibroblasts ( + PD1 + T cells in mice and humans with NASH (Pfister et al., 2021)

Look for cloudiness, particles, color changes, or sediment